Showing: 4 - 6 of 6 RESULTS
Banner News Research News

KemPharm to acquire Orphazyme and pursue FDA approval for Arimoclomol

Arimoclomol treatment. On May 15, 2022, KemPharm, Inc., a specialty pharmaceutical company focused on rare central nervous system diseases like NPC, announced its acquisition from Orphazyme of Arimoclomol. This action supports the confidence of NPC clinicians in the benefit of Arimoclomol. “We believe the efficacy signal for Arimoclomol in NPC is convincing and that there …